Risk factors for late-onset ventilator-associated pneumonia in trauma patients receiving selective digestive decontamination

Intensive Care Med. 2005 Jan;31(1):64-70. doi: 10.1007/s00134-004-2514-z. Epub 2004 Dec 2.

Abstract

Objective: To determine the independent risk factors for late-onset ventilator-associated pneumonia (VAP) in trauma patients receiving selective digestive decontamination (SDD).

Design: A 4-year, prospective cohort study of trauma patients meeting the following criteria: injury severity score >15, and duration of mechanical ventilation >5 days. Predictors of late-onset VAP occurrence were assessed by logistic regression analysis.

Population: All patients received SDD consisting of polymixin E, gentamicin, and amphotericin B applied in nostrils, mouth, and gut with a 3-day course of parenteral cefazolin. VAP was suspected on clinical and radiological signs, and confirmed by the presence of at least one microorganism at a concentration of at least 10(4) CFU/ml on the broncho-alveolar lavage.

Measurement: Independent risk factors for late-onset VAP.

Results: A late-onset VAP was diagnosed in 90 (56%) out of 159 patients. Predicting factors for late-onset VAP were: use of non-depolarizing muscle relaxant agents for intubation [3.4 (CI 1.08-10.73)], duration of intubation [1.06 (CI 1.01-1.17)], length of intensive care unit (ICU) stay [1.05 (CI 1.02-1.09)], and prior tracheal colonization [1.03 (CI 1.02-1.21)]. Exposure to prior antimicrobial treatment, except SDD, conferred protection [0.3 (0.12-0.74)].

Conclusion: This study confirms the role of duration of intubation, length of ICU stay, and prior tracheal colonization in the development of late-onset VAP. The results also highlight the importance of the initial management on the development of late-onset VAP. The type of neuromuscular blocking agents to intubate trauma patients should be evaluated in future studies.

MeSH terms

  • Adult
  • Amphotericin B / therapeutic use
  • Anti-Bacterial Agents / therapeutic use*
  • Female
  • Gentamicins / therapeutic use
  • Hospital Mortality
  • Humans
  • Injury Severity Score
  • Intensive Care Units
  • Logistic Models
  • Male
  • Pneumonia / etiology*
  • Prospective Studies
  • Respiration, Artificial / adverse effects*
  • Risk Factors
  • Wounds and Injuries / classification
  • Wounds and Injuries / complications*

Substances

  • Anti-Bacterial Agents
  • Gentamicins
  • Amphotericin B